China Daily Global Weekly

Pfizer treatment gains conditiona­l approval

-

China’s top drug regulator has given conditiona­l approval for Pfizer’s COVID-19 treatment Paxlovid, making it the first oral pill for the disease approved in the country.

The drug can be used to treat adults who have mild to moderate symptoms and a high risk of progressin­g to more severe disease, the National Medical Products Administra­tion said on Feb 12.

Clinical trial data released by Pfizer found that Paxlovid could reduce the risk of COVID-19-related hospitaliz­ation or death by 87.8 percent when given within five days of the onset of symptoms. The drug was also found effective against the prevailing variants, including the Delta and Omicron variants.

As of Feb 12, Paxlovid is authorized for emergency use and has been granted conditiona­l marketing approval in about 40 countries.

Newspapers in English

Newspapers from United States